Phase 3 Readout~month

Phase 3 Topline: A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Bas

March 1, 2029

Company: Ascendis Pharma A/S (ASND)
Drug: once-weekly
Indication: Turner Syndrome; Idiopathic Short Stature; Short Stature Homeobox Gene Mutation

Other upcoming events for ASND

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi

Patent ExpiryPatent/Exclusivity Expiry: YORVIPATH

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Bas — ASND Phase 3 Readout | BioSniper